Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients

Ji, Hezhao; Li, Yang; Liang, Binhua; Pilon, Richard; MacPherson, Paul; Bergeron, Michèle; Kim, John; Graham, Morag; Van Domselaar, Gary; Sandstrom, Paul; Brooks, James
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Dried blood spots (DBS) are an alternative specimen collection format for HIV-1 genotyping. DBS produce HIV genotyping results that are robust and equivalent to plasma when using conventional sequencing methods. However, using tagged, pooled pyrosequencing, we demonstrate that concordance between plasma and DBS is not absolute and varies according to viral load (VL), duration of HIV infection and antiretroviral therapy (ART) status. The plasma/DBS concordance is the highest when VL is ≥5,000 copies/ml and/or the patient has no ART exposure and/or when the duration of HIV infection is ≤2 years. Stepwise regression analysis revealed that VL is most important independent predictor for concordance of DBS with plasma genotypes. This is the first study to use next generation sequencing to identify discordance between DBS and plasma genotypes. Consideration should be given to VL, duration of infection, and ART exposure when interpreting DBS genotypes produced using next generation sequencing. These findings are of particular significance when DBS are to be used for clinical monitoring purposes.


Related Articles

  • Evolutionary pathways of transmitted drug-resistant HIV-1. Pingen, Marieke; Nijhuis, Monique; de Bruijn, Johan A.; Boucher, Charles A. B.; Wensing, Annemarie M. J. // Journal of Antimicrobial Chemotherapy (JAC);Jul2011, Vol. 66 Issue 7, p1467 

    Several large studies in Europe and the USA revealed that approximately 10% of all newly diagnosed patients harbour HIV-1 variants with at least one major resistance-associated mutation. In this review we discuss the underlying mechanisms that drive the evolution of drug-resistant viruses after...

  • Molecular Epidemiology of HIV-1 in Panama: Origin of Non-B Subtypes in Samples Collected from 2007 to 2013. Mendoza, Yaxelis; Bello, Gonzalo; Castillo Mewa, Juan; Martínez, Alexander A.; González, Claudia; García-Morales, Claudia; Avila-Ríos, Santiago; Reyes-Terán, Gustavo; Pascale, Juan M. // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Phylogenetic studies have suggested that the HIV-1 epidemic in the Americas is mainly dominated by HIV subtype B. However, countries of South America and the Caribbean have recently reported changes in their circulating HIV-1 genetic profiles. The aim of this study was to characterize the...

  • Virtual Screening for Potential Substances for the Prophylaxis of HIV Infection in Libraries of Commercially Available Organic Compounds. Lagunin, A. A.; Filimonov, D. A.; Gloriozova, T. A.; Tarasova, O. A.; Zakharov, A. V.; Guasch, L.; Nicklaus, M. C.; Poroikov, V. V. // Pharmaceutical Chemistry Journal;Oct2013, Vol. 47 Issue 7, p343 

    The search for new substances for the treatment and prophylaxis of HIV-AIDS remains relevant despite advances in highly active antiretroviral therapy (HAART), both because of the appearance of resistance to existing agents and because of their side effects and toxicity. Preventing the spread of...

  • Daily pill can end HIV epidemic. Coghlan, Andy; MacKenzie, Debora // New Scientist;7/23/2011, Vol. 211 Issue 2822, p6 

    The article discusses antiretroviral drugs (ARVs), drugs which may be able to help people who have been infected with HIV live longer and prevent people from being infected with the disease. Two studies presented at an HIV and AIDS conference in Rome, Italy showed that pre-exposure prophylaxis...

  • Tipranavir/T20-based salvage regimens highly effective and durable against HIV-1 with evidence for genotypic predictability of response in clinical practice. Gupta, R. K.; Loveday, Clive; Kalidindi, U.; Lechelt, M.; Skinner, Celia; Orkin, Chloe // International Journal of STD & AIDS;Sep2007, Vol. 18 Issue 9, p630 

    Escalating drug resistance in treatment-experienced HIV-1-infected patients has made management increasingly difficult. In clinical trials, tipranavir (TPV) has produced potent and durable responses in such patients, although experience in clinical cohorts is limited. A retrospective clinical...

  • The impact of the phase of an epidemic of sexually transmitted infection on the evolution of the organism. K M E Turner // Sexually Transmitted Infections;Apr2002, Vol. 78 Issue 0, pi20 

    The evolution of any sexually transmitted organism will be influenced by prevailing epidemiological interactions. The optimum strategy for an organism to overcome treatment, either through drug resistance or cryptic infections, depends upon whether the method for identifying patients is passive...

  • Highlights from this issue. Cassell, Jackie A. // Sexually Transmitted Infections;Jun2015, Vol. 91 Issue 4, p227 

    An introduction is presented in which the editor discusses various reports within the issue on topics including threat of antimicrobial resistant (AMR) gonorrhoea, vulnerability of an AMR gonocoocal transmission model, and the condom use data from a diary study.

  • the drugs don't work. Galliano, Joe // Gay Times (09506101);Jun2003, Issue 297, p53 

    Deals with the instances of gonorrhea as of June 2003. Finding on a study by the Health Protection Agency on antibiotic resistance in gonorrhea; Symptoms of gonorrhea; Consequences if left untreated; Defenses against sexually transmitted diseases.

  • Neisseria gonorrhoeae and Chlamydia trachomatis infection in HIV-1-infected women taking antiretroviral therapy: a prospective cohort study from Burkina Faso. Low, Andrea J.; Konate, Issouf; Nagot, Nicolas; Weiss, Helen A.; Mabey, David; Segondy, Michel; Vickerman, Peter; Meda, Nicolas; de Perre, Philippe van; Mayaud, Philippe // Sexually Transmitted Infections;Mar2014, Vol. 90 Issue 2, p100 

    Objectives Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) are common sexually transmitted infections (STI). We assessed the cumulative risk of NG and CT in a cohort of HIV-1-infected high-risk women taking antiretrovirals over 4 years in Burkina Faso. Methods Between March 2007 and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics